Profile data is unavailable for this security.
About the company
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
- Revenue in USD (TTM)113.63m
- Net income in USD28.02m
- Incorporated2010
- Employees119.00
- LocationCytomX Therapeutics Inc151 Oyster Point Blvd., Suite 400SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 515-3185
- Fax+1 (650) 351-0353
- Websitehttps://cytomx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arrivent Biopharma Inc | 0.00 | -151.40m | 883.01m | 52.00 | -- | 2.87 | -- | -- | -4.24 | -4.24 | 0.00 | 7.47 | 0.00 | -- | -- | 0.00 | -48.90 | -- | -51.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.09 | -- | -- | -- |
| Palvella Therapeutics Inc | 0.00 | -35.07m | 921.83m | 14.00 | -- | 22.32 | -- | -- | -3.83 | -3.83 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -80.19 | -31.18 | -96.21 | -43.15 | -- | -- | -- | -122.22 | -- | -3.05 | 0.2929 | -- | -100.00 | -- | 28.97 | -- | -- | -- |
| GH Research PLC | 0.00 | -42.92m | 953.39m | 50.00 | -- | 3.27 | -- | -- | -0.7313 | -0.7313 | 0.00 | 4.70 | 0.00 | -- | -- | 0.00 | -17.11 | -12.39 | -17.83 | -12.66 | -- | -- | -- | -- | -- | -- | 0.002 | -- | -- | -- | -9.48 | -- | -- | -- |
| Aktis Oncology Inc | 5.56m | -60.65m | 962.34m | -- | -- | -- | -- | 173.08 | -1.20 | -1.20 | 0.1098 | 3.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,090.81 | -- | -- | -- | 0.00 | -- | -- | -- | -53.56 | -- | -- | -- |
| AbCellera Biologics Inc | 35.32m | -171.68m | 963.86m | 596.00 | -- | 0.9987 | -- | 27.29 | -0.5765 | -0.5765 | 0.1187 | 3.22 | 0.0257 | -- | 0.97 | 59,268.46 | -12.49 | 2.01 | -13.20 | 2.20 | -- | -- | -486.01 | 10.48 | -- | -- | 0.00 | 0.00 | -24.17 | 19.95 | -11.24 | -- | 81.35 | -- |
| CytomX Therapeutics Inc | 113.63m | 28.02m | 965.78m | 119.00 | 14.16 | 8.76 | 32.97 | 8.50 | 0.4027 | 0.4027 | 0.9733 | 0.6506 | 0.7646 | -- | 45.63 | 954,882.40 | 18.85 | -15.58 | 40.91 | -26.48 | -- | -- | 24.66 | -50.39 | -- | -- | 0.00 | -- | 36.45 | 19.16 | 5,700.88 | -- | -38.41 | -- |
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 967.73m | 162.00 | -- | 6.55 | -- | 6.78 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Ventyx Biosciences Inc | 0.00 | -106.61m | 1.00bn | 83.00 | -- | 5.20 | -- | -- | -1.50 | -1.50 | 0.00 | 2.68 | 0.00 | -- | -- | 0.00 | -41.60 | -50.81 | -43.60 | -53.75 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.97 | -- | -- | -- |
| Vir Biotechnology Inc | 16.86m | -499.65m | 1.01bn | 408.00 | -- | 1.27 | -- | 60.07 | -3.62 | -3.62 | 0.1223 | 5.73 | 0.0134 | -- | -- | 41,323.53 | -39.69 | -4.58 | -42.97 | -5.34 | 95.94 | -- | -2,963.54 | -13.27 | -- | -- | 0.00 | -- | -13.90 | 55.77 | 15.14 | -- | -3.97 | -- |
| Geron Corp | 183.40m | -79.99m | 1.03bn | 229.00 | -- | 4.13 | -- | 5.60 | -0.1202 | -0.1202 | 0.2754 | 0.3896 | 0.3623 | 0.073 | 5.79 | 800,886.40 | -15.80 | -47.39 | -20.34 | -60.65 | 97.70 | -- | -43.61 | -871.15 | 4.87 | -4.25 | 0.4999 | -- | 32,386.92 | 178.45 | 5.19 | -- | 10.49 | -- |
| Iovance Biotherapeutics Inc | 250.43m | -397.63m | 1.03bn | 838.00 | -- | 1.43 | -- | 4.12 | -1.20 | -1.20 | 0.7552 | 1.82 | 0.2642 | 4.22 | 4.09 | 298,836.50 | -41.94 | -50.14 | -48.13 | -56.84 | 23.96 | -- | -158.78 | -1,097.64 | 3.00 | -- | 0.0014 | -- | 13,698.99 | -- | 16.18 | -- | 9.86 | -- |
| CareDx Inc | 358.00m | 60.76m | 1.04bn | 644.00 | 25.06 | 3.34 | 13.80 | 2.90 | 0.8055 | 0.8055 | 6.15 | 6.05 | 0.7874 | 4.87 | 6.25 | 555,897.50 | 13.37 | -11.64 | 16.67 | -13.85 | 67.62 | 66.00 | 16.97 | -18.51 | 2.75 | -- | 0.00 | -- | 19.07 | 21.31 | 127.62 | -- | 14.13 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -135.27m | 1.04bn | 106.00 | -- | 2.56 | -- | -- | -1.73 | -1.73 | 0.00 | 4.18 | 0.00 | -- | -- | 0.00 | -36.90 | -36.70 | -39.10 | -38.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.96 | -- | 9.12 | -- |
| Savara Inc | 0.00 | -115.65m | 1.06bn | 59.00 | -- | 9.58 | -- | -- | -0.535 | -0.535 | 0.00 | 0.5461 | 0.00 | -- | -- | 0.00 | -60.91 | -36.72 | -66.05 | -39.40 | -- | -- | -- | -109,477.80 | -- | -- | 0.2399 | -- | -- | -- | -75.29 | -- | -29.93 | -- |
| Sana Biotechnology Inc | 0.00 | -234.41m | 1.07bn | 194.00 | -- | 5.37 | -- | -- | -0.9708 | -0.9708 | 0.00 | 0.7447 | 0.00 | -- | -- | 0.00 | -47.13 | -39.42 | -51.39 | -43.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.82 | -- | 5.06 | -- |
Data as of Feb 10 2026. Currency figures normalised to CytomX Therapeutics Inc's reporting currency: US Dollar USD
41.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 13.07m | 7.93% |
| Tang Capital Management LLCas of 30 Sep 2025 | 11.07m | 6.71% |
| Perceptive Advisors LLCas of 30 Sep 2025 | 9.68m | 5.87% |
| Commodore Capital LPas of 30 Sep 2025 | 7.69m | 4.66% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.61m | 4.61% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 4.25m | 2.58% |
| Point72 Asset Management LPas of 30 Sep 2025 | 4.07m | 2.47% |
| Adar1 Capital Management LLCas of 30 Sep 2025 | 4.05m | 2.45% |
| Balyasny Asset Management LPas of 30 Sep 2025 | 3.91m | 2.37% |
| Kynam Capital Management LPas of 30 Sep 2025 | 3.65m | 2.21% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
